KRAS mutations detected in the serum of patients with mCRC have been proposed to monitor response to treatment before the clinical appearance of disease progression whereas in NSCLC patients it has been reported a higher sensitivity for EGFR mutation detection in cfDNA than in CTCs [7], [8], [42]. Here, KRAS is linked to non-small cell lung carcinoma.